What Twist Bioscience does

Twist Bioscience Corporation (NASDAQ: TWST), founded in 2013 and headquartered in South San Francisco, is a public synthetic biology company that manufactures synthetic DNA and related products on a proprietary semiconductor-based silicon platform. The core technology writes DNA directly onto silicon chips at densities up to 10,000x higher than conventional phosphoramidite chemistry, enabling massive parallel synthesis at lower cost. The product portfolio spans synthetic DNA products (clonal genes, gene fragments, gene pools, vectors, multiplexed gene fragments, oligo pools, variant libraries), next-generation sequencing (NGS) consumables (target enrichment panels, library preparation kits including TrueAmp, cfDNA and PCR-Free WGS kits, synthetic viral controls), and antibody discovery services that incorporate in vitro and in vivo capabilities (via the Abveris subsidiary), antibody engineering, and the newly licensed B-Body bispecific antibody platform.

The company monetizes through one-time product sales of synthetic DNA and NGS consumables priced via quote-based enterprise pricing (with a 30% promotional discount for new Multiplexed Gene Fragments customers) plus professional-service fees for antibody discovery, AI-enabled drug discovery CRO work, and biopharma partnerships. Go-to-market combines direct enterprise field sales to biopharma and academic customers, a self-serve e-commerce platform (ecommerce.twistdna.com), programmatic ordering via the Twist API (TAPI), and embedded integrations with platforms such as Benchling, Volta Labs Callisto, and AWS Amazon Bio Discovery. Customer segments are diverse: biopharmaceutical companies (Bayer, Broad Institute, Voyager Therapeutics, Memorial Sloan Kettering) for antibody and nucleic acid therapeutics, academic and research institutions (UC Berkeley, University of Missouri) for genomics and synthetic biology, agricultural biotechnology firms (Phytoform Labs) for crop engineering, and diagnostics/clinical research organizations for liquid biopsy and MRD applications.

Twist reported Q2 FY2026 revenue of $110.7M (+19.3% YoY), its 13th consecutive quarter of sequential growth, with FY2026 guidance of $442–447M (17–19% projected growth), a Q2 gross margin of 51.6% trending toward 55%+, $172M in net cash with no debt, and a path to Q4 adjusted EBITDA breakeven. Recent strategic moves include selection as the wet-lab partner for AWS's Amazon Bio Discovery platform, launch of Complex Genes for AI-generated sequences, the Invenra B-Body bispecific license, and ecosystem integrations with Benchling, LenioBio, and Volta Labs, all oriented toward capturing share of the projected $12B long-term addressable market by 2030.

Name

Twist Bioscience

Legal name

Twist Bioscience Corporation

Website

https://twistbioscience.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Twist Bioscience is a public synthetic biology company that uses a proprietary semiconductor-based silicon platform to manufacture synthetic DNA, NGS consumables, and antibody discovery services for biopharmaceutical, academic, agricultural biotechnology, and diagnostics customers.

Ownership category

akta.pro rank

Product category

Synthetic Biology / DNA Synthesis

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

akta.pro secondary industries

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

Keywords

• Synthetic DNA manufacturing
• Gene synthesis services
• Oligonucleotide pool production
• Next-generation sequencing panels
• Antibody discovery services

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Synthetic DNA Products: Sale of synthetic genes, gene fragments, oligo pools, and variant libraries for research applications. Products include clonal genes, gene pools, vectors, multiplexed gene fragments, and express genes for various downstream applications including therapeutics development and agricultural biotechnology
2. NGS Products and Services: Next-generation sequencing consumables including target enrichment panels, library preparation kits, synthetic controls, and RNA sequencing solutions. Includes fixed content panels (exome, methylation, viral), custom panels, and automation solutions
3. Biopharma Services: Antibody discovery and development services including in vitro and in vivo antibody discovery, antibody engineering and optimization, production, and characterization. Also includes bispecific antibody platform services through Invenra partnership
4. AI-Enabled Drug Discovery: Wet-lab partnership services for AI-driven drug discovery workflows, serving as CRO partner for platforms like AWS Amazon Bio Discovery, providing DNA synthesis and testing services for computational biology applications

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Twist Bioscience manufactures synthetic DNA products (genes, gene fragments, oligo pools, variant libraries) using a proprietary semiconductor-based silicon platform, and supplies next-generation sequencing consumables (target enrichment panels, library preparation kits, synthetic controls). The company also provides antibody discovery and biopharma services, including in vitro and in vivo antibody screening, bispecific antibody development through the licensed B-Body platform, and wet-lab services supporting AI-driven drug discovery workflows.

Product overview

Twist Bioscience is a synthetic biology company offering a semiconductor-based DNA synthesis platform. The product portfolio centers on DNA synthesis products (Genes including Clonal Genes, Gene Fragments, Complex Genes, Gene Pools, Vectors; and Oligo Pools) and Next-Generation Sequencing (NGS) solutions including target enrichment panels, library preparation kits (TrueAmp, cfDNA Library Prep), and synthetic controls. The company also provides Antibody Discovery Services including in vitro/in vivo discovery, the B-Body bispecific antibody platform, and Variant Libraries (combinatorial, SOLD, site saturation). These products are complemented by an API (TAPI) for programmatic access. The platform serves biopharma, academic research, and agricultural biotechnology customers with AI-enabled drug discovery capabilities through partnerships with AWS, Benchling, and LenioBio.

Differentiator

Problem solved

Functional benefit

Products and services

• Genes Twist Bioscience's core gene synthesis product enabling researchers to order synthetic DNA genes for protein expression, metabolic engineering, and pathway construction. Includes clonal genes, gene fragments, gene pools, vectors, express genes, and multiplexed gene fragments.
• Clonal Genes Synthetically manufactured genes delivered as single bacterial colonies with guaranteed sequence accuracy, ideal for protein expression and downstream applications requiring clonal DNA.
• Complex Genes Early access product enabling synthesis of complex DNA sequences up to 7,000 base pairs with approximately 99.5% acceptance rate. Targets previously difficult-to-manufacture sequences including tandem repeats, inverted repeats, and high/low GC content regions for AI-enabled drug discovery and nucleic acid therapeutics.
• Oligo Pools High-throughput oligonucleotide pool synthesis enabling CRISPR screens, gene assembly, and other applications requiring large numbers of oligos. Includes cloned oligo pools and standard oligo pools.
• Variant Libraries Comprehensive variant library products including combinatorial variant libraries, spread-out low diversity (SOLD) libraries, site saturation libraries, and TCR libraries for protein engineering and functional genomics applications.
• NGS Target Enrichment Solutions Comprehensive next-generation sequencing solutions including custom panels, fixed content panels, target enrichment panels, and library preparation kits enabling precise sequencing across various applications such as cancer research, liquid biopsy, and infectious disease surveillance.
• TrueAmp Library Preparation Kit NGS library preparation kit enabling high uniformity across GC-rich, AT-rich, and repeat-dense regions for next-generation sequencing workflows.
• cfDNA Library Prep Kit with TrueAmp Polymerase Mix Cell-free DNA library preparation kit for liquid biopsy and cancer research applications, enabling sensitive detection of circulating tumor DNA.
• MRD Express Minimal residual disease detection panel enabling sensitive tracking of cancer recurrence through liquid biopsy testing.
• Synthetic Controls Synthetic RNA and DNA standards for assay development including SARS-CoV-2 controls, monkeypox virus controls, and respiratory virus controls for quality control and validation.
• Antibody Discovery Services Full-service antibody discovery and development offerings including in vitro discovery, in vivo discovery (via Abveris), antibody engineering and optimization, production and characterization, and bispecific antibodies through the B-Body platform.
• B-Body Bispecific Antibody Platform Licensed bispecific antibody discovery platform enabling co-exclusive development and marketing of bispecific therapeutics, with 20% royalty on clinical trial revenue.
• Twist API (TAPI) Programmatic API enabling developers to integrate DNA synthesis ordering, gene ordering, and other lab services directly into their workflows and systems, supporting automated order placement and integration with platforms like Benchling.

Quantifiable outcome

• DNA synthesis density up to 10,000x higher than conventional methods
• +4 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability7 records

Feature4 records

Partnerships

Six partnerships are on record, tiered core.

• Volta LabscoreTechnology or Integration · 1 June 2026Launch of Twist Fast Hybridization App on Volta Labs Callisto Sample Prep System, completing the full Twist hybrid capture portfolio on the platform. Automated workflow reduces hybridization from overnight to same-day processing while maintaining equivalent sequencing performance.
• LenioBiocoreStrategic or Co-development Partner · 8 May 2026Strategic partnership integrating LenioBio's ALiCE cell-free protein expression platform with Twist's DNA manufacturing capabilities to accelerate AI-driven protein and antibody design services. ALiCE enables production of full-length, folded, functional proteins within 24 hours, compressing design-build-test cycles for AI workflows.
• BenchlingcoreTechnology or Integration · 1 May 2026One-Click Ordering integration enabling scientists to design experiments, submit orders, and receive structured results directly within Benchling platform. Integration creates continuous feedback loop tying orders to experimental context for downstream analysis and model training.
• Amazon Web Services (AWS)coreTechnology or Integration · 1 April 2026AWS selected Twist Bioscience as wet-lab partner for Amazon Bio Discovery, an AI-powered drug discovery platform. Twist provides DNA synthesis and wet-lab testing services for computationally designed antibody candidates, enabling rapid lab-in-the-loop experimentation cycles for biopharma researchers.
• Ginkgo BioworkscoreTechnology or Integration · 1 April 2026CRO partner for Amazon Bio Discovery platform providing synthetic DNA, protein expression, biophysical characterization, and developability assay services for AI-driven drug discovery workflows.
• InvenracoreTechnology or Integration · 1 February 2026Co-exclusive licensing agreement for B-Body bispecific antibody platform, expanding Twist's biologics discovery services. Twist paid $5 million in cash and approximately $15 million in Twist common stock, with Invenra receiving 20% royalty on license revenue from customers entering human clinical trials.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• GenScript: GenScript is a direct competitor in synthetic gene synthesis, gene fragments, oligo pools, and protein/antibody services, with comparable offerings across Twist's core product lines.
• Integrated DNA Technologies (IDT, Danaher): IDT is a leading competitor in synthetic DNA, oligos, and NGS library preparation, serving similar biopharma and academic customers with overlapping product portfolios.
• Eurofins Genomics: Eurofins Genomics offers gene synthesis, oligo synthesis, and NGS services, directly competing with Twist in synthetic DNA and sequencing consumables.
• Synthego: Synthego specializes in synthetic biology, CRISPR reagents, and gene synthesis, competing with Twist's oligo pools and gene fragment products for research and therapeutic customers.

Emerging players

• DNA Script: DNA Script is an emerging competitor using enzymatic DNA synthesis, an alternative to Twist's silicon-based phosphoramidite platform, targeting the same synthetic DNA market.
• AbCellera Biologics: AbCellera is an AI-driven antibody discovery company overlapping with Twist's biopharma services segment, particularly the in vivo and in vitro antibody discovery offerings.
• Absci: Absci is a direct AI drug discovery partner of Twist and also a competitor in generative AI antibody design, sharing the AI biology infrastructure narrative.
• Codexis: Codexis is a protein engineering platform company using directed evolution, adjacent to Twist's variant library and protein engineering offerings for therapeutics applications.

Broad incumbents

• Ginkgo Bioworks: Ginkgo Bioworks is a synthetic biology services platform that is both a CRO partner of Twist on Amazon Bio Discovery and a broader competitor in cell engineering and biologics services.
• 10x Genomics: 10x Genomics is a broader incumbent in genomics tools and NGS workflows, competing with Twist in the sequencing consumables and target enrichment space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/TwistBioscience
• YouTubeyoutube.com/channel/UCXlma642mHPdoJKJNAKZkYg
• LinkedInlinkedin.com/company/twist-bioscience
• Instagraminstagram.com/twist_bioscience
• Facebookfacebook.com/TwistBioscience

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds11 records

Investors28 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Twist Bioscience